Survival improvement in thoracic cancer: progress from the last decade and beyond.

Survival improvement in thoracic cancer: progress from the last decade and beyond. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Survival improvement in thoracic cancer: progress from the last decade and beyond. Abstract Text:

Christian Manegold,Nicholas Thatcher,

Lung cancer remains a major concern, being the most common cancer worldwide, and with the incidence continuing to increase in many countries. Survival following diagnosis of non-small cell lung cancer (NSCLC) remains relatively low, with 1-year overall survival being approximately 25%. However, the development of new drugs and innovative treatment approaches is improving the outlook for patients with NSCLC. Important contributions have been made to the treatment of NSCLC and continue to do so with the development of gemcitabine, and more recently, pemetrexed. Major advances in the understanding of cancer biology have identified many potential targets for rationally designed novel therapies. Many of these targets are components of signalling pathways or metabolic processes that contribute to one of the hallmarks of the cancer phenotype. The novel targeted therapy enzastaurin, which is a derivative of the prototypical protein kinase C inhibitor staurosporine, is currently being investigated as monotherapy in NSCLC following first- or second-line chemotherapy. Research into the use of pharmacogenomics to tailor therapy to the individual patient is another innovative field that is yielding promising results that may help to improve the clinical outcome for patients with NSCLC in the future.

Survival improvement in thoracic cancer: progress from the last decade and beyond. Publishing Authors By Initials

C Manegold,N Thatcher,

For similar biological sciences: biology: genetics: pharmacogenetics research abstracts see: biological sciences: biology: genetics: pharmacogenetics research

PUBMED ID PMID:

MEDLINE DATE:

Survival improvement in thoracic cancer: progress from the last decade and beyond. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Lung cancer (Amsterdam, Netherlands)

VOLUME: 57 Suppl 2

Page Numbers: S3-5

Journal Abbreviation: Lung Cancer

ISSN: 0169-5002

DAY: 29

MONTH: Aug

YEAR: 2007

Survival improvement in thoracic cancer: progress from the last decade and beyond. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8800805

Survival improvement in thoracic cancer: progress from the last decade and beyond. Keywords Mesh Terms:

KEYWORDS: Pharmacogenetics

MESH TERMS: mortality

Chemical & Substance for Abstract: Survival improvement in thoracic cancer: progress from the last decade and beyond. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Survival improvement in thoracic cancer: progress from the last decade and beyond.

AFFILIATION: Heidelberg University, Interdisciplinary Thoracic Oncology and Department of Surgery, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. christian.manegold@chir.ma.uni-heidelberg.de

Country: Ireland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Lung Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Survival improvement in thoracic cancer: progress from the last decade and beyond Related Publications

• Activation of estrogen receptor-mediated gene transcription by the equine estrogen metabolite, 4-methoxyequilenin, in human breast cancer cells.
• Antibiotics in foods: a review of some public health aspects.
• Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
• Cloned ovarian cells from sheep: Cholesterol dependency in progesterone synthesis.
• Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo.
• Concentration of phenylbutazone (PBZ) and 13, 14-dihydro-15 keto PGF(2alpha) (PGFM) in blood and seminal plasma of stallions treated with PBZ.
• Cortical reorganization in deaf children.
• Effects of calving-related disorders on prostaglandin, calcium, ovarian activity and uterine involution in postrartum dairy cows.
• Effects of dietary unsaturated fatty acids on oocyte quality and follicular development in lactating dairy cows in summer.
• Effects of postinsemination progesterone supplementation on fertility and subsequent estrous responses of dairy heifers.
• Embryonic development in superovulated dairy cattle exposed to elevated ambient temperatures between Days 1 to 7 post insemination.
• Fetal survival in the cow after pregnancy diagnosis by palpation per rectum.
• Follicular dynamics and superovulatory response in Holstein cows treated with FSH-P in different endocrine states.
• HEALTH PROBLEMS IN THE FOOD INDUSTRY.
• Influence of summer heat stress on pregnancy rates of lactating dairy cattle following embryo transfer or artificial insemination.
• Influences of in vitro oocyte aging on microfertilization in the mouse with reference to zona hardening.
• Potential mechanisms of estrogen quinone carcinogenesis.
• Pregnancy, bovine somatotropin, and dietary n-3 Fatty acids in lactating dairy cows: III. Fatty acid distribution.
• Pregnancy, bovine somatotropin, and dietary n-3 fatty acids in lactating dairy cows: I. Ovarian, conceptus, and growth hormone-insulin-like growth factor system responses.
• Pregnancy, bovine somatotropin, and dietary n-3 fatty acids in lactating dairy cows: II. Endometrial gene expression related to maintenance of pregnancy.
• Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection.
• Regulation of heat shock-induced alterations in the release of prostaglandins by the uterine endometrium of cows.
• Secretion of PGF2alpha and oxytocin during hyperthermia in cyclic and pregnant heifers.
• Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
• Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
• Survival improvement in thoracic cancer: progress from the last decade and beyond.
• The effects of ACTH on the renin-aldosterone system in normotensive man.
• The long-term pattern of adult mortality and the highest attained age.
• The place of targeted therapy in the patient management of non-small cell lung cancer.
• The role of potassium as cause of death in experimental trypanosomiasis.